<code id='6897A650A1'></code><style id='6897A650A1'></style>
    • <acronym id='6897A650A1'></acronym>
      <center id='6897A650A1'><center id='6897A650A1'><tfoot id='6897A650A1'></tfoot></center><abbr id='6897A650A1'><dir id='6897A650A1'><tfoot id='6897A650A1'></tfoot><noframes id='6897A650A1'>

    • <optgroup id='6897A650A1'><strike id='6897A650A1'><sup id='6897A650A1'></sup></strike><code id='6897A650A1'></code></optgroup>
        1. <b id='6897A650A1'><label id='6897A650A1'><select id='6897A650A1'><dt id='6897A650A1'><span id='6897A650A1'></span></dt></select></label></b><u id='6897A650A1'></u>
          <i id='6897A650A1'><strike id='6897A650A1'><tt id='6897A650A1'><pre id='6897A650A1'></pre></tt></strike></i>

          fashion

          fashion

          author:hotspot    Page View:164
          A Exterior of the new Ultragenyx biomanufacturing plant. -- biotech coverage from STAT
          Jonathan Wiggs /Globe Staff

          Ultragenyx said Thursday afternoon that its gene therapy for a rare liver ailment, glycogen disease type 1A, succeeded in a Phase 3 trial, setting up a potential approval.

          Patients with GSD1a, as the condition is often known, have a genetic mutation that prevents them from adequately maintaining blood sugar levels. Once considered fatal, GSD1a can now be controlled with regular doses of cornstarch. But if patients miss a dose, there can be significant, even life-threatening, complications.

          advertisement

          In the 49-person, randomized study, patients who received the Ultragenyx drug were able to take 41% less cornstarch after 48 weeks than they did at the start. Patients on placebo took only 10% less. The difference was statistically significant. Five patients were not included in the analysis, as three dropped out and the company didn’t have 48-week data from two.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Wikipedia

          The high cost of giving birth even with insurance
          The high cost of giving birth even with insurance

          AdobeTheburdenofhighhealthcarecostsandmedicaldebtintheU.S.isnosecret.Medicaldebtaffectsoneinfiveadul

          read more
          Inflation cooled significantly in June, bringing price hikes close to normal levels
          Inflation cooled significantly in June, bringing price hikes close to normal levels

          1:39ProducepricesaredisplayedatagrocerystoreinBrooklyn,Feb.14,2023.XinhuaNewsAgencyviaGettyImagesCon

          read more
          Anesthesiologist group: stop taking Ozempic before surgery
          Anesthesiologist group: stop taking Ozempic before surgery

          EspeciallyinthefirstweeksoftakingdrugslikeOzempic,foodstayslongerinthestomach—aprobleminsurgeries.Ad

          read more

          Women's World Cup brings attention to abuse in soccer

          FILE-RepublicofIreland'sSineadFarrelly,center,greetsplayersaftertheteam'smatchwiththeUnitedStatesina